Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02452983

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 
This pilot study investigates clinical benefit of four 28-day cycles of sertraline in low-risk MDS patients. Participants will receive 100mg of oral sertraline daily. The study will also evaluate potential associated biological mechanisms of action.
Status: 
Recruiting
Study Date: 
Sat, 05/02/2015 to Thu, 06/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Sertraline Other Name: Zoloft Procedure: Bone Marrow Aspirate/Biopsy